Harbor Capital Advisors Inc. Acquires 15,200 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Harbor Capital Advisors Inc. lifted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 11.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 153,907 shares of the company's stock after buying an additional 15,200 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.56% of Castle Biosciences worth $4,389,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. RiverPark Advisors LLC boosted its position in shares of Castle Biosciences by 362.2% in the first quarter. RiverPark Advisors LLC now owns 2,861 shares of the company's stock valued at $63,000 after acquiring an additional 2,242 shares during the period. US Bancorp DE boosted its position in shares of Castle Biosciences by 1,889.2% in the third quarter. US Bancorp DE now owns 4,615 shares of the company's stock valued at $132,000 after acquiring an additional 4,383 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Castle Biosciences by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company's stock valued at $152,000 after acquiring an additional 2,093 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Castle Biosciences by 10.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company's stock valued at $215,000 after purchasing an additional 952 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Castle Biosciences in the second quarter valued at $218,000. Institutional investors own 92.60% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CSTL. Robert W. Baird raised their target price on Castle Biosciences from $34.00 to $37.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 6th. Canaccord Genuity Group lifted their price objective on Castle Biosciences from $35.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, October 29th. Stephens reaffirmed an "overweight" rating and issued a $37.00 price target on shares of Castle Biosciences in a report on Tuesday, August 6th. Finally, BTIG Research lifted their price target on Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a report on Monday, October 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $35.14.

Castle Biosciences Stock Performance

Shares of CSTL stock traded up $0.49 during trading on Monday, reaching $33.64. 721,321 shares of the company's stock were exchanged, compared to its average volume of 319,327. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $928.80 million, a PE ratio of -233.36 and a beta of 0.98. Castle Biosciences, Inc. has a twelve month low of $16.20 and a twelve month high of $35.42. The firm's fifty day moving average price is $30.57 and its 200-day moving average price is $25.48.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.47. The firm had revenue of $87.00 million for the quarter, compared to analyst estimates of $69.95 million. Castle Biosciences had a negative return on equity of 0.77% and a negative net margin of 1.08%. During the same period in the prior year, the firm posted ($0.70) EPS. As a group, sell-side analysts anticipate that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Insider Buying and Selling

In other news, insider Derek J. Maetzold sold 986 shares of the stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the completion of the sale, the insider now owns 94,622 shares of the company's stock, valued at approximately $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Derek J. Maetzold sold 986 shares of the firm's stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $28.73, for a total transaction of $28,327.78. Following the completion of the sale, the insider now owns 94,622 shares of the company's stock, valued at $2,718,490.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Derek J. Maetzold sold 1,972 shares of the firm's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $32.27, for a total value of $63,636.44. Following the completion of the sale, the insider now directly owns 91,664 shares of the company's stock, valued at $2,957,997.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,694 shares of company stock worth $820,497 in the last ninety days. 7.20% of the stock is owned by insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.